Diagnósticos da América Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van Diagnósticos da América is gedaald met een gemiddeld jaarlijks percentage van -58.2%, terwijl de winst van de Healthcare -industrie jaarlijks groeide met 18.2%. De inkomsten zijn groeide met een gemiddeld percentage van 23.4% per jaar.
Belangrijke informatie
-58.2%
Groei van de winst
-51.7%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 11.6% |
| Inkomstengroei | 23.4% |
| Rendement op eigen vermogen | -9.9% |
| Nettomarge | -5.9% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Some Diagnósticos da América S.A. (BVMF:DASA3) Shareholders Look For Exit As Shares Take 27% Pounding
Nov 15
Diagnósticos da América (BVMF:DASA3) Has Some Way To Go To Become A Multi-Bagger
Nov 13Revenues Working Against Diagnósticos da América S.A.'s (BVMF:DASA3) Share Price Following 27% Dive
Aug 15Diagnósticos da América (BVMF:DASA3) Use Of Debt Could Be Considered Risky
Jul 23Benign Growth For Diagnósticos da América S.A. (BVMF:DASA3) Underpins Stock's 30% Plummet
Jun 24Why Investors Shouldn't Be Surprised By Diagnósticos da América S.A.'s (BVMF:DASA3) 25% Share Price Plunge
May 10Risks To Shareholder Returns Are Elevated At These Prices For Diagnósticos da América S.A. (BVMF:DASA3)
Mar 21Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital
Feb 04Is Diagnósticos da América (BVMF:DASA3) A Risky Investment?
Jan 08Insufficient Growth At Diagnósticos da América S.A. (BVMF:DASA3) Hampers Share Price
Dec 18Diagnósticos da América (BVMF:DASA3) Is Reinvesting At Lower Rates Of Return
Sep 20Is Diagnósticos da América (BVMF:DASA3) Using Too Much Debt?
Aug 25Diagnósticos da América S.A. (BVMF:DASA3) Looks Inexpensive But Perhaps Not Attractive Enough
Jun 27Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital
Apr 17Diagnósticos da América (BVMF:DASA3) Seems To Be Using A Lot Of Debt
Mar 13Returns On Capital At Diagnósticos da América (BVMF:DASA3) Paint A Concerning Picture
Dec 14Does Diagnósticos da América (BVMF:DASA3) Have A Healthy Balance Sheet?
Nov 09Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital
Aug 19Here's Why Diagnósticos da América (BVMF:DASA3) Has A Meaningful Debt Burden
Jul 15Diagnósticos da América (BVMF:DASA3) May Have Issues Allocating Its Capital
May 06Results: Diagnósticos da América S.A. Delivered A Surprise Loss And Now Analysts Have New Forecasts
Apr 01These 4 Measures Indicate That Diagnósticos da América (BVMF:DASA3) Is Using Debt Reasonably Well
Mar 02Diagnósticos da América (BVMF:DASA3) Could Be Struggling To Allocate Capital
Jan 25Diagnósticos da América (BVMF:DASA3) Might Be Having Difficulty Using Its Capital Effectively
Oct 10Is Diagnósticos da América (BVMF:DASA3) A Risky Investment?
Sep 13There Are Reasons To Feel Uneasy About Diagnósticos da América's (BVMF:DASA3) Returns On Capital
Jun 27Diagnósticos da América (BVMF:DASA3) Has A Somewhat Strained Balance Sheet
May 31We're Watching These Trends At Diagnósticos da América (BVMF:DASA3)
Feb 25Shareholders of Diagnósticos da América (BVMF:DASA3) Must Be Delighted With Their 634% Total Return
Jan 03
These 4 Measures Indicate That Diagnósticos da América (BVMF:DASA3) Is Using Debt Extensively
Dec 07Opbrengsten en kosten
Hoe Diagnósticos da América geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 14,971 | -879 | 2,937 | 0 |
| 30 Jun 24 | 14,771 | -972 | 2,947 | 0 |
| 31 Mar 24 | 14,446 | -1,150 | 2,987 | 0 |
| 31 Dec 23 | 14,252 | -1,138 | 2,975 | 0 |
| 30 Sep 23 | 14,213 | -843 | 3,044 | 0 |
| 30 Jun 23 | 13,869 | -752 | 2,762 | 0 |
| 31 Mar 23 | 13,527 | -590 | 2,746 | 0 |
| 31 Dec 22 | 13,129 | -387 | 2,864 | 0 |
| 30 Sep 22 | 12,523 | -340 | 2,930 | 0 |
| 30 Jun 22 | 11,862 | -177 | 2,814 | 0 |
| 31 Mar 22 | 11,178 | -177 | 3,136 | 0 |
| 31 Dec 21 | 10,419 | -227 | 3,066 | 0 |
| 30 Sep 21 | 9,973 | -36 | 3,105 | 0 |
| 30 Jun 21 | 9,280 | -60 | 2,736 | 0 |
| 31 Mar 21 | 7,959 | -85 | 1,997 | 0 |
| 31 Dec 20 | 7,039 | -151 | 1,635 | 0 |
| 30 Sep 20 | 5,887 | -191 | 1,269 | 0 |
| 30 Jun 20 | 4,986 | -198 | 1,271 | 0 |
| 31 Mar 20 | 4,795 | -19 | 1,249 | 0 |
| 31 Dec 19 | 4,365 | 125 | 1,148 | 0 |
| 30 Sep 19 | 4,238 | 127 | 1,129 | 0 |
| 30 Jun 19 | 4,096 | 158 | 1,097 | 0 |
| 31 Mar 19 | 3,992 | 168 | 1,070 | 0 |
| 31 Dec 18 | 3,933 | 184 | 1,046 | 0 |
| 30 Sep 18 | 3,886 | 210 | 899 | 0 |
| 30 Jun 18 | 3,733 | 175 | 875 | 0 |
| 31 Mar 18 | 3,545 | 136 | 841 | 0 |
| 31 Dec 17 | 3,399 | 131 | 823 | 0 |
| 30 Sep 17 | 3,259 | 129 | 791 | 0 |
| 30 Jun 17 | 3,178 | 152 | 715 | 0 |
| 31 Mar 17 | 3,138 | 169 | 665 | 0 |
| 31 Dec 16 | 3,041 | 95 | 652 | 0 |
| 30 Sep 16 | 2,965 | 90 | 596 | 0 |
| 30 Jun 16 | 2,899 | 39 | 592 | 0 |
| 31 Mar 16 | 2,864 | 29 | 606 | 0 |
| 31 Dec 15 | 2,794 | 24 | 605 | 0 |
| 30 Sep 15 | 2,731 | 4 | 604 | 0 |
| 30 Jun 15 | 2,731 | 38 | 610 | 0 |
| 31 Mar 15 | 2,691 | 58 | 588 | 0 |
| 31 Dec 14 | 2,698 | 88 | 576 | 0 |
| 30 Sep 14 | 2,666 | 135 | 604 | 0 |
| 30 Jun 14 | 2,584 | 127 | 564 | 0 |
| 31 Mar 14 | 2,528 | 130 | 532 | 0 |
| 31 Dec 13 | 2,448 | 125 | 490 | 0 |
Kwaliteitswinsten: DASA3 is momenteel verliesgevend.
Groeiende winstmarge: DASA3 is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: DASA3 is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 58.2% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van DASA3 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: DASA3 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Healthcare industrie ( 64.3% ).
Rendement op eigen vermogen
Hoge ROE: DASA3 heeft een negatief Return on Equity ( -9.95% ), omdat het momenteel verliesgevend is.